| Expression pattern: |
UP |
| Associated gene: |
HLA-A*11:01 |
| Associated microRNA: |
- |
| Biological function: |
elicits antigen-specific CD8+ T cell responses; MYH9_2-trained T cells specifically target and kill tumor-derived organoids |
| Molecular mechanism: |
circRNA translation produces neoepitopes (eg, MYH9_2) that bind HLA-A*11:01, activate CD8+ T cells, and mediate tumor-specific killing |
| Biological pathway or process: |
immune regulation (promotes); other pathway/process (other) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RT-qPCR; divergent primers PCR; Sanger Sequencing; Back-Splice Junction PCR / divergent primers PCR; ELISA; Flow Cytometry（Non-apoptosis/cycle）; Bioinformatics Analysis; In Vivo Animal Model |
| Clinical significance: |
detectable and enriched in CRC liquid biopsies; supports a detection-to-vaccination strategy; potential CRC vaccine neoantigen source |
| Description: |
circMYH9 is upregulated in CRC tumors and provides translatable neoepitopes (notably MYH9_2) that trigger CD8+ T-cell responses. MYH9_2-trained T cells preferentially kill tumor organoids, and circMYH9 is detectable/enriched in CRC liquid biopsy samples, supporting biomarker-guided vaccination. |
| Confidence score: |
0.6716 |